tiprankstipranks
DMK Pharmaceuticals Faces Nasdaq Suspension and Delisting
Company Announcements

DMK Pharmaceuticals Faces Nasdaq Suspension and Delisting

DMK Pharmaceuticals (DMK) has released an update to notify the public and investors about listing compliance status.

Don't Miss Our Christmas Offers:

DMK Pharmaceuticals Corporation’s common stock was suspended from trading on the Nasdaq Stock Market as of February 7, 2024. Following this suspension, the company is set to face delisting, with a formal notification to be filed with the U.S. Securities and Exchange Commission.

For further insights into DMK stock, check out TipRanks’ Stock Analysis page.

For a comprehensive understanding of the announcement, you can read the full document here.

Related Articles
TipRanks Auto-Generated NewsdeskDMK Pharmaceuticals Warns Investors Amid Bankruptcy
TipRanks Auto-Generated NewsdeskDMK Pharmaceuticals Expects Nasdaq Delisting Amid Bankruptcy
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App